

TABLE OF CONTENTS

S. No.	Title	Page No.
	Declaration	ii
	Abstract	iii-vii
	Acknowledgement	viii-ix
	Table of Contents	x-xv
	List of Figures	xvi-xviii
	List of Tables	xix-xxi
	List of Publications	xxii
	List of Abbreviations	xxii-xxvi
Chapter 1	INTRODUCTION	1-48
1.1	Psoriasis	1
1.2	Skin a route for novel drug delivery	3
1.3	Pathophysiology of Psoriasis	5
1.4	Epidemiology	7
1.5	Etiology of psoriasis	7
1.5.1	Genetics	7
1.5.2	Medications	8
1.5.3	Lifestyle	9
1.5.4	Oxidative pressure	9
1.6	Types of psoriasis	9
1.7	Conventional Treatment	12
1.8	Challenges in Topical Delivery of Drugs in Psoriatic Skin	21
1.9	Clobetasol propionate	26
1.9.1	Primary characteristics	27
1.9.2	Pharmacokinetics	27
1.9.3	Mechanism of action	28
1.10	Requirement for Novel Carriers	29
1.11	Mechanism of Uptake of Novel Carriers	30
1.11.1	Significance of Novel drug delivery systems used in	32

	treatment psoriasis	
1.12	Nanoemulsion	32
1.13	Nanostructured lipid carrier	33
1.13.1	Salient Features of Nanostructured Lipid Carrier (NLC)	35
1.13.2	Type of NLCs	35
1.13.3	Method of preparation of nanostructured lipid carrier (NLCs)	36
1.14	Deformable liposomes	38
1.14.1	Mechanism of Penetration of Deformable liposomes	40
1.15	Nano gel	41
1.15.1	Advantages of using Emulgel as a Drug Delivery System	42
1.16	Research Envisaged	43
1.17	Research Objectives	46
1.18	Plan of work	46
Chapter 2	LITERATURE REVIEW	49-68
Chapter 3	BIOACTIVE AND EXCIPIENTS PROFILE	69-74
3.1	Profile of Bioactive Clobetasol Propionate	69
3.1.1	Clobetasol Propionate	69
3.2	Excipient Profile	70
3.2.1	Surfactants	70
3.2.1.1	Pluronic F-68	71
3.2.1.2	Soya Phosphatidylcholines	71
3.2.2	Squalene	72
3.2.3	Sodium cholate	73
Chapter 4	EXPERIMENTAL (MATERIALS AND METHODS)	75-96
4.1	Chemicals and Excipients Materials and Equipment	75
4.2	Preformulation studies of Bioactive (clobetasol propionate)	78
4.2.1	Drug identification	78
4.2.2	Physical appearance	78

4.2.3	Melting point	79
4.2.4	Solubility studies	79
4.2.5	FT-IR determination	80
4.2.6	Partition coefficient	80
4.2.7	Standard curve of clobetasol propionate in Octanol	80
4.2.8	Standard curve of clobetasol propionate in 10% methanolic phosphate buffer (PBS) (pH 5.5)	81
4.3	Methodology	81
4.3.1	Method of preparation of nanoemulsion	82
4.3.2	Method of preparation of nanostructured lipid carrier	83
4.3.3	Method of preparation of deformable liposomes	84
4.4	Characterization of nanoemulsions, nanostructured lipid carrier and deformable liposomes	85
4.4.1	Determination of particle size, polydispersity index and zeta potential	85
4.4.2	Entrapment Efficiency of NLCs and Deformable liposomes.	86
4.4.3	Percentage drug loading in NLCs and Deformable liposomes.	86
4.5	Preparation of gel	87
4.6	Incorporation of nanoemulsion or nlcs or deformable liposomes into carbopol 940 solution	87
4.7	Characterization of gel formulation	87
4.7.1	Physical examination	87
4.7.2	pH	88
4.7.3	Viscosity	88
4.7.4	Drug content	88
4.7.5	Spreadability	88
4.8	<i>In vitro</i> drug release study	89
4.8.1	<i>In vitro</i> drug release study of nanoemulsion	89
4.8.2	<i>In vitro</i> drug release study of NLCs	89
4.8.3	<i>In vitro</i> drug release study of Deformable liposomes	89

4.9	Physical storage stability studies	90
4.10	<i>In-vivo</i> studies	90
4.10.1	Experimental protocol:	90
4.10.2	Disease induction	91
4.10.3	Antipsoriatic activity.	91
4.10.4	Route of administration and withdrawal of blood samples	91
4.11	Ex-vivo skin permeation studies	93
4.12	Ex-vivo Skin deposition studies	93
4.12.1	Preparation of sebum removed skin	94
4.13	Skin irritation study	94
4.14	Histopathology	95
4.15	HPLC bioanalytical method Development	95
4.15.1	Instrumentation and Conditions	95
4.15.2	Method development for the determination of clobetasol propionate in plasma	95
Chapter 5	RESULTS AND DISCUSSION	97-143
5.1	Preformulation Studies	97
5.1.1.	Melting Point	97
5.1.2.	Solubility studies	97
5.1.3.	FT-IR Spectroscopy	98
5.1.4.	Partition Coefficient	99
5.1.5.	Standard Curve of Clobetasol Propionate in 10 % Methanolic PBS at 239nm at pH 5.5	99
5.1.6.	Standard Curve of Clobetasol Propionate in Octanol at 239 nm	100
5.2	Preparation optimization and characterization of clobetasol propionate loaded nanocarriers.	102
5.2.1.	Preparation & Characterization of Clobetasol Propionate Loaded Nanoemulgel.	102
5.2.1.1.	Optimization of the Blank and Drug-Loaded Nanoemulsion.	102

5.2.1.2.	Morphology	107
5.2.1.3.	DSC study	107
5.2.1.4.	Optimization and characterization of Gel	109
5.2.1.5.	Spreadability of optimized blank nanoemulgel (F30)	109
5.2.1.6.	Spreadability of optimized nanoemulgel (F31)	110
5.2.1.7.	Rheology	111
5.2.1.8.	Percentage <i>in vitro</i> release graph of clobetasol propionate in 10% methanolic PBS (pH 5.5)	112
5.2.2.	Preparation & Characterization of Clobetasol Propionate Loaded Nanostructured Lipid Carrier	113
5.2.2.1.	Optimization of Blank and Drug-Loaded Nanostructured Lipid Carrier	113
5.2.2.2.	Drug loaded NLCs	116
5.2.2.3.	Morphology	118
5.2.2.4.	Differential Scanning Calorimetry	118
5.2.2.5.	Preparation and characterization of gel containing nanostructured lipid carrier	120
5.2.2.6.	Texture analysis of gel	121
5.2.2.7.	Rheological behavior of optimized formulation (F28 D)	122
5.2.2.8.	<i>In-vitro</i> drug release studies	122
5.2.3.	Optimization of the Blank and Drug-Loaded deformable liposomes.	124
5.2.3.1.	Centrifugation Test	127
5.2.3.2.	Morphology	127
5.2.3.3.	Optimization and characterization of Gel	127
5.2.3.4.	Rheology	128
5.2.3.5.	Percentage <i>in vitro</i> release graph of clobetasol propionate in 10% methanolic PBS (pH 5.5)	129
5.2.4.	Ex-Vivo Studies on Rat Psoriatic Skin	130
5.2.4.1	Ex-Vivo Skin Permeation Studies of nanoemulgel	130
5.2.4.2	In- Vitro Skin Deposition Studies	131
5.2.4.3	Drug Delivery via Sebum-Removed Skin	131

5.2.4.4.	Ex-Vivo Skin Permeation Studies of NLCs (10% Methanolic PBS pH 5.5)	132
5.2.4.5.	Percentage Drug Retention Studies in 10% Methanolic PBS at pH 5.5	133
5.2.4.6.	Drug Delivery via Sebum-Removed Skin	134
5.2.4.7.	Percentage Drug Retention Studies of Deformable liposomes in 10% Methanolic PBS at pH 5.5	135
5.2.5.	Physical stability studies	136
5.2.6.	Pharmacokinetic study	137
5.2.7.	<i>In-vivo</i> studies	139
5.2.7.1	Skin irritation studies	139
5.2.7.2	Histopathology	141
Chapter 6	SUMMARY AND CONCLUSION	144-150
6.1	Summary	144
6.2	Conclusion	150
	REFERENCES	151-172
	APPENDIX	